RNS Number : 3978Z Microsaic Systems plc

15 May 2023

15 May 2023

Microsaic Systems plo

("Microsaic" or the "Company")

Audit update

Microsaic Systems plc (AIM: MSYS), the developer of micro-electronic instruments and analytical solutions, wishes to provide an update on the expected date of its audited results for the year to 31 December 2022 (the "FY22 Results").

On 18 April 2023, the Company announced that it expected to release its FY22 Results during the first half of May 2023. As the audit is taking longer than initially anticipated, the FY22 Results are now expected to be published on or before 30 June 2023.

Enquiries:

Microsaic Systems plc +44 (0) 734 0055 648

Gerry Brandon, Acting Executive Chairman

+44 (0)20 7496 3000

Singer Capital Markets (Nominated Adviser & Joint Broker)

Aubrey Powell / George Tzimas

Turner Pope Investments (TPI) Limited (Joint Broker)

Andy Thacker / James Pope

+44 (0) 20 3657 0050

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information as stipulated under the UK version of the market abuse regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

About Microsaic Systems

Microsaic floated on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested c. £30m over 20 years of development, Microsaic has a robust and innovative patent portfolio in cutting-edge technology designed and developed for "Industry 4.0" application. Microsaic serves markets in Human Health, Environmental Health and Diversified Industries. Microsaic's system solutions enable analytical detection and characterisation at the point-of-need, whether within a conventional laboratory setting, or within a bioprocessing facility for continuous MS detection data at multiple steps in the process workflow.

Microsaic's products and systems are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing and point of need applications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

MSCEAKSSFESDEEA